1. Home
  2. AGEN vs CHRS Comparison

AGEN vs CHRS Comparison

Compare AGEN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGEN
  • CHRS
  • Stock Information
  • Founded
  • AGEN 1994
  • CHRS 2010
  • Country
  • AGEN United States
  • CHRS United States
  • Employees
  • AGEN N/A
  • CHRS N/A
  • Industry
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AGEN Health Care
  • CHRS Health Care
  • Exchange
  • AGEN Nasdaq
  • CHRS Nasdaq
  • Market Cap
  • AGEN 87.7M
  • CHRS 102.0M
  • IPO Year
  • AGEN 2000
  • CHRS 2014
  • Fundamental
  • Price
  • AGEN $5.29
  • CHRS $0.91
  • Analyst Decision
  • AGEN Strong Buy
  • CHRS Buy
  • Analyst Count
  • AGEN 3
  • CHRS 3
  • Target Price
  • AGEN $16.33
  • CHRS $4.68
  • AVG Volume (30 Days)
  • AGEN 1.2M
  • CHRS 1.4M
  • Earning Date
  • AGEN 08-11-2025
  • CHRS 08-11-2025
  • Dividend Yield
  • AGEN N/A
  • CHRS N/A
  • EPS Growth
  • AGEN N/A
  • CHRS N/A
  • EPS
  • AGEN N/A
  • CHRS N/A
  • Revenue
  • AGEN $99,524,000.00
  • CHRS $272,251,000.00
  • Revenue This Year
  • AGEN $25.31
  • CHRS N/A
  • Revenue Next Year
  • AGEN N/A
  • CHRS $142.61
  • P/E Ratio
  • AGEN N/A
  • CHRS N/A
  • Revenue Growth
  • AGEN N/A
  • CHRS 19.87
  • 52 Week Low
  • AGEN $1.38
  • CHRS $0.66
  • 52 Week High
  • AGEN $7.34
  • CHRS $2.43
  • Technical
  • Relative Strength Index (RSI)
  • AGEN 44.92
  • CHRS 50.88
  • Support Level
  • AGEN $5.34
  • CHRS $0.84
  • Resistance Level
  • AGEN $6.58
  • CHRS $1.15
  • Average True Range (ATR)
  • AGEN 0.44
  • CHRS 0.07
  • MACD
  • AGEN -0.16
  • CHRS -0.01
  • Stochastic Oscillator
  • AGEN 10.69
  • CHRS 22.14

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: